Recombinant human VEGF Receptor 2 protein (Active) (ab106310)
Key features and details
- Expression system: Insect cells
- Purity: > 95% SDS-PAGE
- Active: Yes
- Suitable for: Functional Studies, SDS-PAGE
製品の詳細
-
製品名
Recombinant human VEGF Receptor 2 protein (Active)
VEGF Receptor 2 タンパク質・ペプチド 製品一覧 -
生理活性
Measured by its ability to inhibit the VEGF165-induced proliferation in human umbilical vein endothelial (HUVE) cells.
-
精製度
> 95 % SDS-PAGE.
Affinity purified. -
発現系
Insect cells -
アクセッション番号
-
タンパク質長
Full length protein -
Animal free
No -
由来
Recombinant -
-
生物種
Human -
配列
The soluble receptor protein consists of the first 6 extracellular domains and contains the unique C-terminal end of native Human soluble VEGF Receptor 2 (CGRETILDHSAEAVGMP) [Albuquerque et al.,Nature Medicine,2009] generated by alternative splicing. -
予測される分子量
105 kDa
-
特性
Our Abpromise guarantee covers the use of ab106310 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
アプリケーション
Functional Studies
SDS-PAGE
-
製品の状態
Lyophilized -
備考
Endotoxin level: < 0.1 ng per ug. Measured by its ability to bind to immobilized recombinant Human VEGF165 in a functional ELISA. -
Concentration information loading...
前処理および保存
-
保存方法および安定性
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Constituents: 0.4875% MES, 0.87% Sodium chloride
This product is an active protein and may elicit a biological response in vivo, handle with caution.
-
再構成The lyophilized powder should be reconstituted in water or PBS to a concentration not lower than 100 µg/ml.
関連情報
-
別名
- CD309
- CD309 antigen
- EC 2.7.10.1
see all -
機能
Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. -
関連疾患
Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. -
配列類似性
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
翻訳後修飾
Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. -
細胞内局在
Membrane. - Information by UniProt
画像
-
Inhibition of the VEGF165-induced proliferation in HUVECs by soluble VEGFR-2/KDR. VEGF165 (10ng/ml) was preincubated with increasing amounts of sVEGFR-2/KDR for 1h and then added to the cells.
-
Inhibition of the VEGF165-induced proliferation of HUVE cells by recombinant human and mouse endogenous sKDR and sFlk-1 HUVECs were stimulated with 10 ng/ml VEGF165, both soluble receptors were added with a 100X excess.
-
SDS-PAGE showing ab106310
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
Datasheet download
参考文献 (0)
ab106310 は論文での使用が確認できていません。